| | | |

New Hope for Relapsed Pleural Mesothelioma?

ByAlex Strauss
relapsed pleural mesothelioma

There is new evidence that adding a drug called vorinostat to immunotherapy might help relapsed pleural mesothelioma patients. 

The new study comes from the Moffitt Cancer Center in Tampa. It focused on patients with non-small cell lung cancer. Non-small cell lung cancer is similar to pleural mesothelioma in many ways. 

The study found that patients who received vorinostat along with an immune checkpoint inhibitor had better results. The findings could be good news for relapsed pleural mesothelioma patients, too.

Different Immunotherapy Drugs

Vorinostat is sold under the brand name Zolinza. It is a histone deacetylase (HDAC) inhibitor. HDAC inhibitors alter the way proteins are expressed inside cells. They also stimulate the immune system. 

Immune checkpoint inhibitors (ICIs) like Keytruda also stimulate the immune system. ICIs block proteins like PD-1 that help mesothelioma cells evade detection. Drugs like Keytruda are among the most promising new mesothelioma treatment approaches. 

Relapsed pleural mesothelioma can happen when patients become resistant to their ICI. The new study shows vorinostat helped Keytruda work again in mice with relapsed lung cancer. 

“HDAC inhibitors improve response to PD-1 blockade in mouse models of lung cancer by increasing T-cell trafficking to tumors and enhancing T-cell function,” says Amer Beg, PhD, an immunologist at Moffitt.

Second-Line Treatment Needed for Relapsed Pleural Mesothelioma

Right now, there is no second-line treatment for relapsed pleural mesothelioma. A 2011 study of vorinostat for mesothelioma produced disappointing results. That study tested vorinostat as a stand-alone treatment.

The Moffitt study is the first one to combine vorinostat with an ICI in lung cancer. After the encouraging results in mice, researchers tested the combination in 33 human lung cancer patients. 

The treatment caused fatigue, nause, and vomiting in about a third of patients. But 67 percent of them experienced at least a partial response. Tumors stopped growing in 16 patients. Patients who had higher levels of T cells before treatment had the best results. 

The results of the Moffiitt study suggest that vorinostat may boost the effectiveness of Keytruda for relapsed pleural mesothelioma. 

The next step is a phase 2 trial of vorinostat and Keytruda as a first-line lung cancer treatment. 

Source:

“New Drug Combination Shows Promising Activity in Non-Small Cell Lung Cancer Patients”, August 27, 2019, Moffit Cancer Center website, https://moffitt.org/newsroom/press-release-archive/2019/new-drug-combination-shows-promising-activity-in-non-small-cell-lung-cancer-patients/

Gray, J, et al, “Phase 1/1b study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer”, August 24, 2019, Clinical Cancer Research, https://clincancerres.aacrjournals.org/content/early/2019/08/13/1078-0432.CCR-19-1305

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…